<DOC>
	<DOC>NCT00877955</DOC>
	<brief_summary>This study tests the assumption that the bioavailability of alprazolam from a new sublingual formulation is the same as that from sublingual formulation expected to be used commercially in Brazil.</brief_summary>
	<brief_title>Bioequivalence Of A Test Alprazolam Sublingual Formulation Compared To A Commercial Sublingual Formulation</brief_title>
	<detailed_description />
	<mesh_term>Alprazolam</mesh_term>
	<criteria>Healthy male or female subjects BMI 17.5 30.5 Must provide informed consent Clinically significant disease Narrow angle glaucoma Positive drug screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>alprazolam</keyword>
	<keyword>sublingual</keyword>
</DOC>